microRNA 6516 (miR-6516)

**MicroRNA 6516 (miR-6516)** is a short non-coding RNA molecule belonging to the class of microRNAs, which post-transcriptionaly regulate gene expression by binding to complementary sequences on target mRNAs, resulting in gene silencing through translation inhibition or mRNA degradation[3][1]. In humans, it exists as hsa-miR-6516 and has different mature forms including miR-6516-3p and miR-6516-5p. miR-6516 has been functionally linked to diverse biological and pathological processes: - In muscle, miR-6516 acts as an inhibitor of muscle atrophy, with evidence indicating it modulates the expression of genes such as CDKN1B to preserve muscle integrity during disuse or wasting[1]. - In lupus nephritis, miR-6516-3p has been found to exacerbate disease by suppressing RECK, an inhibitor of MMP-9, resulting in increased MMP-9 activity in renal mesangial cells and contributing to tissue damage under inflammatory conditions[3]. - In cancer, the miR-6516-5p isoform functions within competing endogenous RNA (ceRNA) networks and can be regulated by sponge lncRNAs (e.g., SNHG20), affecting oncogenic and metastatic processes[2]. - In metabolic syndrome, miR-6516-5p is significantly downregulated in patient plasma and serves as a potential novel biomarker for early disease detection and risk stratification[4]. miR-6516 is not a classical druggable receptor or enzyme but may represent a promising therapeutic target or biomarker for several chronic diseases where dysregulated post-transcriptional gene regulation is implicated. **No known direct small-molecule or biologic drugs currently target miR-6516 in clinical practice, but approaches utilizing miRNA mimics or inhibitors (antagomirs) could be envisioned for future therapeutic development.**

Other names

hsa-miR-6516hsa-miR-6516-3phsa-miR-6516-5pmiR-6516MIR6516microRNA mir-6516

Gene silencing via mRNA cleavage/degradation or translation inhibition of target genes such as RECK (a negative regulator of MMP-9), CDKN1B, NPPC, PRND, and USP25[1][3]. Inhibition of MMP-9 regulatory pathways resulting in altered inflammatory responses[3].